CA3245873A1 - Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations - Google Patents

Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations

Info

Publication number
CA3245873A1
CA3245873A1 CA3245873A CA3245873A CA3245873A1 CA 3245873 A1 CA3245873 A1 CA 3245873A1 CA 3245873 A CA3245873 A CA 3245873A CA 3245873 A CA3245873 A CA 3245873A CA 3245873 A1 CA3245873 A1 CA 3245873A1
Authority
CA
Canada
Prior art keywords
weight
unsaturated
saturated
mixture
triglycerides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3245873A
Other languages
English (en)
Inventor
Daniel Gooding
John Brew
Robin M. Bannister
Original Assignee
Trx Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2022/058180 external-priority patent/WO2022207580A2/fr
Application filed by Trx Biosciences Ltd filed Critical Trx Biosciences Ltd
Publication of CA3245873A1 publication Critical patent/CA3245873A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention divulgue une composition pharmaceutique comprenant un ou plusieurs fibrates, un ou plusieurs glycérolipides et un ou plusieurs activateurs de digestion. Les glycérolipides divulgués comprennent une ou plusieurs graisses solides et une ou plusieurs graisses liquides. Les amplificateurs de digestion divulgués comprennent un ou plusieurs acides biliaires, un ou plusieurs phospholipides, un ou plusieurs acides gras libres en C14-24, un ou plusieurs tensioactifs d'acides gras libres en C14-24 ou une combinaison quelconque associée. La présente invention divulgue également des méthodes et des procédures destinées à formuler lesdits un ou plusieurs fibrates divulgués dans les compositions pharmaceutiques divulguées. La présente invention divulgue en outre des méthodes et des utilisations des compositions pharmaceutiques divulguées dans le traitement d'une inflammation et/ou d'une neuro-inflammation.
CA3245873A 2022-03-14 2023-03-14 Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations Pending CA3245873A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269330P 2022-03-14 2022-03-14
US63/269,330 2022-03-14
PCT/EP2022/058180 WO2022207580A2 (fr) 2021-03-27 2022-03-28 Compositions ayant une biodisponibilité d'agents thérapeutiques améliorée
EPPCT/EP2022/058180 2022-03-28
PCT/EP2023/056506 WO2023174948A2 (fr) 2022-03-14 2023-03-14 Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3245873A1 true CA3245873A1 (fr) 2023-09-21

Family

ID=85571360

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3245873A Pending CA3245873A1 (fr) 2022-03-14 2023-03-14 Compositions possédant une biodisponibilité améliorée d'agents thérapeutiques et leurs utilisations

Country Status (7)

Country Link
EP (1) EP4493151A2 (fr)
JP (1) JP2025509680A (fr)
AU (1) AU2023233811A1 (fr)
CA (1) CA3245873A1 (fr)
IL (1) IL315617A (fr)
WO (1) WO2023174948A2 (fr)
ZA (1) ZA202407659B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025072929A1 (fr) * 2023-09-28 2025-04-03 The Regents Of The University Of California Méthodes et compositions de traitement d'états liés à l'âge
WO2025093572A1 (fr) * 2023-10-29 2025-05-08 TRx Biosciences Limited Compositions de dispersion solide et leurs utilisations
WO2026053168A1 (fr) * 2024-09-06 2026-03-12 Graviton Bioscience Bv Formes amorphes d'un inhibiteur de rock2 et formulations associées

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082667A (en) * 1988-06-07 1992-01-21 Abbott Laboratories Solid pharmaceutical dosage in tablet triturate form and method of producing same
US5885486A (en) * 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US20020028813A1 (en) * 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
EP2220073B1 (fr) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Derivés de pyridazinone inhibiteurs de la parp
ME02640B (fr) * 2008-10-07 2017-06-20 Kudos Pharm Ltd Formulation pharmaceutique 514
CN102307576A (zh) * 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
CN101507707B (zh) * 2009-04-08 2011-01-19 邓菊娟 一种盐酸法舒地尔脂微球制剂及其制备方法
CN101926757B (zh) * 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
CN102813639B (zh) * 2011-06-08 2014-04-30 中国疾病预防控制中心寄生虫病预防控制所 甲苯达唑软胶囊剂
CA2865040C (fr) * 2012-02-21 2020-07-14 Merck Patent Gmbh Derives cycliques de diaminopyrimidine
EA201690608A1 (ru) * 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US11629118B2 (en) * 2017-03-03 2023-04-18 Inspirna, Inc. Formulations with improved stability
AU2019363244B2 (en) * 2018-10-15 2024-10-03 Cipla Limited Pharmaceutical formulation
WO2020217235A1 (fr) * 2019-04-24 2020-10-29 Aizant Drug Research Solutions Private Limited Forme posologique solide de dasatinib
CN113546045B (zh) * 2021-08-18 2022-11-11 浙江大学 恢复肿瘤微环境失活树突状细胞功能的纳米制剂及应用

Also Published As

Publication number Publication date
WO2023174948A3 (fr) 2023-10-26
IL315617A (en) 2024-11-01
AU2023233811A1 (en) 2024-09-19
EP4493151A2 (fr) 2025-01-22
JP2025509680A (ja) 2025-04-11
ZA202407659B (en) 2026-01-28
WO2023174948A2 (fr) 2023-09-21

Similar Documents

Publication Publication Date Title
AU2023233811A1 (en) Compositions having improved bioavailability of therapeutics and uses thereof
Rizvi et al. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model
US6720001B2 (en) Emulsion compositions for polyfunctional active ingredients
AU2016245984B2 (en) Self-emulsifying formulations of DIM-related indoles
Jiang et al. Ionic Liquids: Promising Approach for Oral Drug Delivery: Jiang et al.
CN103002877A (zh) 作为缓解疾病的抗风湿性药（dmard）和抗癌药剂的甲氨蝶呤的持续释放制剂
EP4312978A2 (fr) Compositions ayant une biodisponibilité d'agents thérapeutiques améliorée
Dravid et al. Resolvin D1‐loaded nanoliposomes promote M2 macrophage polarization and are effective in the treatment of osteoarthritis
TW202139984A (zh) 治療性化合物及其調配物與用途
Pangeni et al. Improvements in the oral absorption and anticancer efficacy of an oxaliplatin-loaded solid formulation: pharmacokinetic properties in rats and nonhuman primates and the effects of oral metronomic dosing on colorectal cancer
Caliph et al. The impact of lymphatic transport on the systemic disposition of lipophilic drugs
Shailendrakumar et al. Improved oral pharmacokinetics of pentoxifylline with palm oil and capmul® MCM containing self-nano-emulsifying drug delivery system
CN101780037B (zh) 双嘧达莫自乳化给药系统及其制备方法
JP2023520273A (ja) 治療化合物、製剤、およびその使用
AU2026201779A1 (en) Formulated and/or co-formulated liposome compositions containing IDO antagonist prodrugs useful in the treatment of cancer and methods thereof
JP2009518443A (ja) 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
JP2019513828A (ja) 改善された薬物動態を有するイソフラボノイド組成物
US20250195433A1 (en) Compositions Having Improved Bioavailability of Therapeutics and Uses Thereof
KR20210099038A (ko) 시클로스포린 유사체의 제약 제형
KR101859200B1 (ko) 모노아세틸디아실글리세롤 화합물의 경구 투여용 조성물 및 고형 제제
JP2026505949A (ja) 自己乳化医薬組成物、その製造方法及び使用
US20250195461A1 (en) Fibrate Compositions for Treating Inflammation and Neuroinflammation
CN111065397A (zh) MEK/PI3K、JAK/MEK、JAK/PI3K/mTOR和MEK/PI3K/mTOR生物学途径的抑制剂和用于改善治疗化合物的淋巴摄取、生物利用度和溶解度的方法
CN104703626B (zh) 用于治疗癌症的基于碘油的抗肿瘤乳剂
WO2025093572A1 (fr) Compositions de dispersion solide et leurs utilisations

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240912

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20240917

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240917

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20240917

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20240917

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250213

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250312

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250312

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251224